vidual variations can be anticipated, which surprisingly is recognised by the authors ('patients with hematological malignancies show substantial variations in the peak levels of progenitor cells . . .').
Patients included had very heterogeneous hematological malignancies regarding their mobilization potential due to the previous treatment that they had received. PBSCs in ALL patients are known to be very easy to mobilize, while PBSCs in Hodgkin's disease patients are known to be often very difficult to mobilize due to previous therapy. Under these conditions, it is nearly impossible to consider that the studied population is homogenous, and no evidence is provided by the authors that 'the two groups exhibited identical patient characteristics'.
The number of patients included is very low and very unbalanced: 10 for granocyte, 33 for neupogen. Moreover, they did not receive the same treatment (three of 10 received high-dose cyclophosphamide in the granocyte group, and 20/33 in the neupogen group). Furthermore the administration of G-CSF 8 days after cyclophosphamide is a very uncommon practice.
We have recalculated the Fisher's exact test (P = 0.46) used to demonstrate that three of 10 is no different from 20/33 (ratios of patients treated by cyclophosphamide plus G-CSF in the granocyte and neupogen groups, respectively). Our result is P = 0.148 (Fisher's exact test, two-tailed) instead of P = 0.46 as presented in the paper, which means that despite being 'not statistically different', the two groups are probably 'less similar' than the authors concluded. This is very important since it has been demonstrated that G-CSF plus chemotherapy is more efficient at mobilizing PBSC than G-CSF alone. This creates some doubts about the validity of all the statistical analyses presented, this one being the only one that could be recalculated from available data.
In addition, concomitant CD34 flow cytometry analysis and apheresis studies were performed concomitantly in only eight of 10 patients having received granocyte (how many received cyclophosphamide?) and in only 11/33 having received neupogen (how many received cyclophosphamide?). Reporting 10 and 33 patients when the population studied was only eight and 11, respectively, is misleading.
The primary aim of this study was to compare the mobilization capacity of the two G-CSFs. Thus it is surprising that no numerical data are presented about, for example, the kinetics of peripheral blood CD34 ϩ cell concentration, the number of blood volumes treated and the number of CD34 ϩ cells collected at each apheresis and the total number of aphereses necessary to collect sufficient quantities of CD34 ϩ cells. All these nonreported data are essential to draw any conclusion of clinical value.
The only numerical data presented in the paper are about qualitative analysis of CD34 ϩ cell subsets. However, what is the clinical relevance of such a comparison? The authors show no difference between the two G-CSFs except that granocyte may be more efficient at expanding and mobilizing CD34 ϩ /CD19 ϩ cells. However, the difference is most probably due to previous treatment by cyclophosphamide which is known to decrease CD19 ϩ subsets. Since the proportion of patients having received cyclophosphamide is not known in the small studied population (eight in the granocyte group and 11 in the Neupogen group), this creates again some doubt against the validity of this result.
In conclusion, this study based on small, non-homogeneous diagnostic groups of patients with a non-randomized, non-stratified and non-cross-over design, is misleading and neither confirms nor refutes the results of previously published randomized studies by Höglund et al 4 and Watts et al 5 which showed significant differences in efficacy between glycosylated and non-glycosylated rhG-CSF (namely granocyte and neupogen) at priming progenitor cells on a per g basis.
We hope to read soon in the full-paper section of Bone Marrow Transplantation the results of another welldesigned randomized comparative study, aimed at confirming or refuting the previously published study results of Höglund et al 4 5 which, in contrast to the non-randomized and non-convincing study by Saccardi et al 6 mentioned in Schiodt's paper, have been published in international peer-reviewed journals.
and Watts et al

Response to the comment on 'Flow cytometry comparison of CD34
؉ subsets in bone marrow and peripheral blood after priming with glycosylated or nonglycosylated rhG-CSF' by JM Miclea
The criticism raised by Miclea 1 regarding the design of the study is well taken and we agree that the optimal design would have been a large, double-blind, randomised study concerning a single disease, followed by another study of another disease and so forth. As clinicians, however, it may be necessary to make exploratory studies in order to avoid spending valuable research grants and time on welldesigned studies of limited clinical significance. We believe that this is possible wihout producing misleading information when interpreted with care. Evaluated together with other studies, it may provide sufficient information for the decision to initiate a more extensive, randomised study or not. This was the background for the pilot study 2 based on our hypothesis that qualitative differences after priming with glycosylated rhG-CSF, identified by subset numbers in the mobilised stem cells, should be present in all analysed samples. This was not found and we chose to show these results. However, given the opportunity we would now like to show some additional endpoints analysed ( Table 1) . Some of the patient characteristics are given as well in
JM Miclea
Institut d'Hématologie, C Chomienne
Hôpital Saint Louis, Centre Hayem, Paris, France order to justify the comparison between the two groups ( Table 2) . In clinical practice, however, the important question is perhaps not so much the exact number of CD34 ϩ cells that one can mobilise in the individual patient by the use of a certain growth factor as much as the growth factor's ability to mobilise a sufficient number of stem cells in any patient to achieve a safe autograft by leukapheresis. Our impression after conducting this pilot study is that both the G-CSFs used are excellent for this purpose and that they seem to be equally efficient in equal doses. Still, we do not know if a smaller dose of glycosylated G-CSF is equal to 10 g/kg non-glycosylated G-CSF. We would like to emphasise that this issue was addressed in patients with breast cancer, in a prospective and randomised study, published as a full length article. 3 The conclusions drawn from this study were similar to ours, although bio-equivalent doses were used (mean 8.4 g/kg non-glycosylated vs All patients 36 (7-127) 38 
